Paper42948835PubMed
Blood-Based Biomarkers in Alzheimer's Disease: Advances in Detection Technologies and Clinical Applications.
Li S and 2 others. Aging Med (Milton), 2026.
Cite this record
ConductScience Library. Blood-Based Biomarkers in Alzheimer's Disease: Advances in Detection Technologies and Clinical Applications. Papers, record 42948835. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42948835
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Blood-Based Biomarkers in Alzheimer's Disease: Advances in Detection Technologies and Clinical Applications.
- Journal
- Aging Med (Milton)
- Year
- 2026
- Publication types
- Journal Article, Review
- Revised in PubMed
- 2026-10-29
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References52
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35379992 | New insights into the genetic etiology of Alzheimer's disease and related dementias. | Nat Genet | 2022 | https://conductscience.org/library/papers/35379992 | PubMed |
| 2 | 41768934 | Associations of plasma GFAP and P-tau217 with imaging ATN markers and cognitive decline across Centiloid scales. | Lancet Reg Health West Pac | 2026 | https://conductscience.org/library/papers/41768934 | PubMed |
| 3 | 40636898 | Predicting amyloid status in mild cognitive impairment: the role of semantic intrusions combined with plasma biomarkers. | Front Aging Neurosci | 2025 | https://conductscience.org/library/papers/40636898 | PubMed |
| 4 | 23332364 | Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. | Lancet Neurol | 2013 | https://conductscience.org/library/papers/23332364 | PubMed |
| 5 | 32123386 | Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. | Nat Med | 2020 | https://conductscience.org/library/papers/32123386 | PubMed |
| 6 | 39713875 | Plasma Aβ42/Aβ40 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum. | Alzheimers Dement | 2025 | https://conductscience.org/library/papers/39713875 | PubMed |
| 7 | 41376134 | Plasma P-tau217, GFAP, and NfL as biomarkers for Alzheimer's disease: role in disease stratification, pathological progression, and cognitive decline. | Alzheimers Dement | 2025 | https://conductscience.org/library/papers/41376134 | PubMed |
| 8 | 41287986 | Subjective sleep characteristics in non-demented adults: domain-specific associations with multimodal Alzheimer's disease biomarkers. | Alzheimers Dement | 2025 | https://conductscience.org/library/papers/41287986 | PubMed |
| 9 | 30171200 | Neurofilaments as biomarkers in neurological disorders. | Nat Rev Neurol | 2018 | https://conductscience.org/library/papers/30171200 | PubMed |
| 10 | 40954312 | Primary care detection of Alzheimer's disease using a self-administered digital cognitive test and blood biomarkers. | Nat Med | 2025 | https://conductscience.org/library/papers/40954312 | PubMed |
| 11 | 38252443 | Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. | JAMA Neurol | 2024 | https://conductscience.org/library/papers/38252443 | PubMed |
| 12 | 41457950 | False positive plasma p-tau217 results associated with heterophilic antibody interference: A potential clinical pitfall. | Alzheimers Dement | 2025 | https://conductscience.org/library/papers/41457950 | PubMed |
| 13 | 36918389 | 2023 Alzheimer's disease facts and figures. | Alzheimers Dement | 2023 | https://conductscience.org/library/papers/36918389 | PubMed |
| 14 | 40801297 | Comparison of plasma p-tau217/Aβ42, p-tau217, and Aβ42/Aβ40 biomarkers by race to detect Alzheimer's disease. | Alzheimers Dement | 2025 | https://conductscience.org/library/papers/40801297 | PubMed |
| 15 | 21514248 | Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. | Alzheimers Dement | 2011 | https://conductscience.org/library/papers/21514248 | PubMed |
| 16 | 40976838 | Combining Lumipulse p-tau217 and Aβ42/40 as confirmatory tests for Aβ positivity prior to disease-modifying therapy. | Alzheimers Dement | 2025 | https://conductscience.org/library/papers/40976838 | PubMed |
| 17 | 35022306 | Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease. | Neurology | 2022 | https://conductscience.org/library/papers/35022306 | PubMed |
| 18 | 41537338 | Elecsys pTau217 plasma immunoassay detection of amyloid pathology in clinical cohorts. | Alzheimers Dement | 2026 | https://conductscience.org/library/papers/41537338 | PubMed |
| 19 | 39572740 | Tau filaments are tethered within brain extracellular vesicles in Alzheimer's disease. | Nat Neurosci | 2025 | https://conductscience.org/library/papers/39572740 | PubMed |
| 20 | 38339929 | The Associations of Phosphorylated Tau 181 and Tau 231 Levels in Plasma and Cerebrospinal Fluid with Cognitive Function in Alzheimer's Disease: A Systematic Review and Meta-Analysis. | J Alzheimers Dis | 2024 | https://conductscience.org/library/papers/38339929 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42948835
GET https://conductscience.org/api/papers/v1/42948835/references?page=2